Gapping up
In reaction to earnings/guidance:
- APT +17.9%, MRNA +13%, OCN +12.4%, PBPB +10.5%, BGS +9.4%, INSP +8.5%, ALRM +5.7%, WW +5.1%, AMRX +5%, MTDR +4.9%, ENDP +4.9%, MIDD +4.9%, NVRO +3.4%, HZNP +3.3%, GNL +3.2%, PZZA +2.9%, EYE +2.3%, INN +2.1%, AKCA +1.9%, TROX +1.7%, OUT +1.7%, BHVN +1.7%, AEE +1.7%, INFN +1.5%, WYND +1.5%, CLDT +1.4%, IONS +1.3%, RRD +0.9%, SYX +0.9%, ODP +0.8%, CARS +0.7%
Other news:
- IFRX +21.3% (announces "positive" initial data from Phase IIa open label study if IFX-1 in Pyoderma Gangraenosum)
- MNLO +20% (did not meet primary endpoint in Phase 2 serlopitant for the treatment of chronic pruritus of unknown origin)
- NVAX +3.1% (announces publication of preclinical NanoFu data in Vaccines)
- MEDP +2.2% (files for mixed securities shelf offering)
- RDS.A +0.8% (Bloomberg report that it plans deep water wells in Mexico)
Analyst comments:
- KTOS +2.3% (upgraded to Buy from Hold at Jefferies)
- REGN +1.1% (upgraded to Buy from Hold at Canaccord Genuity)
- SBRA +0.9% (upgraded to Buy from Neutral at Mizuho)
- DPZ +0.5% (upgraded to Buy from Hold at Argus)
